Table 1 Demographic characteristics of the study population
Variable | UC patients without symptoms of anxiety/depression (n = 79) | UC patients with symptoms of anxiety/depression (n = 60) | P-value |
|---|---|---|---|
Age (year), median (IQR) | 32(24,51) | 48(33,55) | 0.0012* |
Male, n (%) | 43(54.43%) | 36(60.00%) | 0.5114 |
Education status | |||
Primary and below | 2(2.53%) | 9(15.00%) | 0.0164* |
Middle school | 19(24.05%) | 17(28.33%) | |
High school | 27(34.18%) | 21(35.00%) | |
Bachelor or above | 31(39.24%) | 13(21.67%) | |
BMI (kg/m2), median (IQR) | 20.30(18.25,22.00) | 20.67(18.27,22.04) | 0.7696 |
Duration of disease(month), median (IQR) | 24(8,60) | 36(16,97) | 0.0969 |
Smoking use, n(%) | |||
Current | 0(0.00%) | 4(6.67%) | 0.0173* |
Quitted | 13(16.46%) | 14(23.33%) | |
Never | 66(83.54%) | 42(70.00%) | |
Surgery, n(%) | 3(3.80%) | 8(13.33%) | 0.0809 |
Montreal classfication, n (%) | |||
E1 | 6(7.59%) | 1(1.67%) | 0.2454 |
E2 | 23(29.11%) | 16(26.67%) | |
E3 | 50(63.29%) | 43(71.67%) | |
Extraintestinal manifestations, n (%) | 10(12.66%) | 16(26.67%) | 0.0359* |
Mayo score, median (IQR) | 8(6,9) | 10(8,11) | < 0.0001* |
Laboratory examination | |||
White blood cell (109/L), median (IQR) | 7.24(5.24,8.83) | 7.39(5.91,9.65) | 0.3234 |
Neutrophil count(109/L), median (IQR) | 4.97(3.20,6.06) | 4.61(3.49,6.82) | 0.5851 |
Neutrophil ratio (%), mean ± SD | 65.77 ± 13.27 | 65.67 ± 12.88 | 0.9656 |
Lymphocyte count (109/L), median (IQR) | 1.40(1.08,2.02) | 1.71(1.20,2.01) | 0.2061 |
Lymphocyte ratio (%), mean ± SD | 23.97 ± 11.32 | 24.04 ± 10.43 | 0.7740 |
Monocyte count(109/L), median (IQR) | 0.43(0.33,0.58) | 0.49(0.38,0.72) | 0.0752 |
Monocyte ratio (%), median (IQR) | 6.5(5.1,8.9) | 7.0(5.6,9.3) | 0.2629 |
Hemoglobin (g/L), median (IQR) | 109(86,131) | 108(90,127) | 0.9282 |
Platelet (109/L), median (IQR) | 256(202,310) | 301(221,398) | 0.0222* |
C-reactive protein(mg/L), median (IQR) | 11.1(2.9,34.3) | 17.5(4.5,56.2) | 0.1594 |
ESR (mm/h), median (IQR) | 27(16,50) | 41(26,69) | 0.0062* |
Albumin(g/L), mean ± SD | 38.27 ± 7.11 | 34.79 ± 7.51 | 0.0061* |
Creatinine(μmol/L), median (IQR) | 61(50,72) | 65(55,78) | 0.1554 |
ASCA positive, n(%) | 39(49.37%) | 27(45.00%) | 0.6096 |
UCEIS, mean ± SD | 4.620 ± 1.727 | 6.033 ± 1.775 | < 0.0001* |
Geboes, median (IQR) | 4.1(3.1,4.2) | 5.1(4.2,5.2) | < 0.0001* |
Current treatmenta | |||
5-Aminosalicylic, n(%) | 58(73.42%) | 40(66.67%) | 0.3873 |
Corticosteroids, n(%) | 23(29.11%) | 35(58.33%) | 0.0005* |
Thiopurines, n(%) | 11(13.92%) | 14(28.33%) | 0.9259 |
Anti-TNF, n(%) | 9(11.39%) | 5(8.33%) | 0.5528 |